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tients and allow for in vivo expansion of adoptively transferred EBV-
CTL.
Study design: The primary objective of this Phase I clinical trial is to
determine the safety of escalating doses of EBV-CTL after CD45MAbs
infusion in EBV-positive NPC patients. The secondary objective is to
determine the expansion, persistence and antitumor effects of infused
EBV-CTL.
Results: Eight patients with advanced stage, refractory/relapsed NPC
have been treated with autologous EBV-CTL (2107-1108 cells/m2
per infusion). Patients received between 1 - 5CTL infusions, which were
well tolerated, although one developed transient swelling at a pre-existing
metastatic disease site. Infusion of CD45 MAbs resulted in a transient
period of neutropenia (ANC 0.5109/L), which resolved within 48
hours. The absolute lymphocyte count decreased 4-fold and approached
baseline within 14 days post infusion. In 6 of 8 patients, we detected
increased IL-15 serum levels, a cytokine important for lymphocyte pro-
liferation. In 3 out of 8 patients EBV-CTL expanded 2.5 to 21-fold
within 8 weeks post infusion as determined by IFN- Elispot assays.
Clinically, 1 patient had a complete response (9 months), 3 had stable
disease for 2 - 16 months, and 4 had progressive disease.
Conclusion: Treatment of EBV-positive NPC with EBV-CTL ap-
pears to be safe and can be associated with signiﬁcant anti-tumor activity.
Administration of CD45 MAbs prior to EBV-CTL infusion resulted in
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To identify the signals controlling cell division symmetry and self-
renewal of hematopoietic stem cells (HSC) we have studied the cell-cell
contact between human HSC and human mesenchymal stem cells
(MSC) derived from themarrow, the latter serving as a surrogate “niche”
in vitro. By applying novel time lapsemicroscopy tomonitor cell divisions
ofHSCand correlating cell division symmetrywithLTC-ICormyeloid-
lymphoid initiating cell (ML-IC) assays at a single cell level, we have
previously demonstrated that only vital human MSC were able to drive
asymmetric divisions and maintain self-renewal. The roles of speciﬁc
homing and adhesion molecules, and of junctions between HSC and
MSCwere studied in the present report. In the ﬁrst 48 hours,  integrins
have been shown to be a major mediator of self-renewing divisions, as
well as CXCR4/SDF-1. However, ligands alone could not recapitulate
the effects of MSC. Subsequent to adhesion, junctions are formed be-
tween HSC and MSC. At the contact zone, N-cadherin, cadherin 11,
protein p120, - and -catenin are highly expressed, as demonstrated by
immunoﬂuorescence and Westernblot. Gene expression analyses have
also shown a signiﬁcant up-regulation of genes coding for adhesion
proteins and extracellular matrix in the adherent subsets of HSC (ﬁ-
bronectin 1, cadherin 11, connexin 43, N-cadherin, ITGBL1, VCAM1
and TGFB1). Upon incubation for further 72 hours, the genes that are
up-regulated in the HSC included the checkpoint (CHK1) homolog
(CHEK1), early growth response protein 1 (EGR-1) and a number of
genes coding for proteins that play a role in proliferation and DNA-
repair. Functionally LTC-IC were found almost exclusively among the
HSC adherent to MSC. Preliminary data from SCID mouse xenotrans-
plantation model indicated that the slow dividing fraction possessed sig-
niﬁcantly higher repopulating potential. Thus, albeit homing and adhe-
sion molecules such as -1- integrins, CXCR4/SDF-1 are essential for
mediating the initial cell-cell interactions leading to self-renewal divisions,
the formation of junctions and activation of the cadherin-catenin system
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Background: In 2, multicenter, randomized trials (N1200), the
incidence of invasive fungal infection (IFI) and associated mortality
were investigated in patients receiving posaconazole (POS) vs ﬂu-
conazole (FLU) or itraconazole (ITZ).
Methods: In double-blind study, 1600 hematopoietic stem cell
transplant (HSCT) recipients with graft-vs-host disease (GVHD)
were randomized to receive POS oral suspension (200 mg t.i.d.) or
FLU tablets (400 mg q.d.). In study 2, 602 neutropenic patients
undergoing chemotherapy for acute myelogenous leukemia (AML)
or myelodysplastic syndrome (MDS) were randomized to receive
either 200 mg t.i.d. oral suspension POS or a standard azole (FLU
suspension 400 mg q.d. or ITZ solution 200 mg b.i.d.). The
incidence of proven/probable IFI was assessed by a blinded expert
panel for the on-treatment phase of study 1 (ﬁrst dose to last dose
plus 7 days) and study 2 (randomization to last dose plus 7 days).
Deaths from any cause during both studies were included in the
mortality analysis. Cause of death was investigator determined.
Results: In study 1, 600 patients were randomized to receive POS
(n301) or FLU (n299). In study 2, 602 patients were randomized to
receive POS (n304) or standard azole (FLU [n240] or ITZ [n58]).
During the on-treatment period, signiﬁcantly fewer IFIs developed in the
POS patient group in both study 1 (2% vs 8%, P0.004) and study 2
(2% vs 8%, P0.0009) compared to the FLUor standard azole (FLUor
ITZ) groups, respectively. In study 1, prophylaxis with POS resulted in
fewer IFIs than with FLU (5% vs 9%, P0.07) during the primary time
period (randomization to day 112). During the period from randomiza-
tion to day 100 in study 2, POS prophylaxis resulted in signiﬁcantly fewer
IFIs than prophylaxis with FLU or ITZ (5% vs 11%, P0.003). Fewer
cases of aspergillosis developed among patients receiving POS prophy-
laxis than among FLU or standard azole prophylaxis patients in both
study 1 (2% vs 7%, P0.006) and study 2 (1% vs 9%, P0.0001). A
signiﬁcant survival beneﬁt was demonstrated in AML/MDS patients
receiving POS prophylaxis (study 2) by Kaplan-Meier analysis of time to
death by any cause (P0.035).
Conclusion: In these 2 studies, prophylaxis with POS resulted in
fewer IFIs than prophylaxis with FLU or ITZ. Mortality rates in
both studies were higher in patients who developed an IFI than in
patients who did not, indicating that prophylaxis is a strategy that
prevents mortality in high-risk patients.
Overall Mortality During Study
Patients With IFI Patients Without IFI
Study 1 Study 2 Study 1 Study 2
n  62 n  32 n  538 n  570
Deaths, n (%) 40(65) 12(38) 120(22) 104(18)
Primary cause of death
IFIs 13(21) 8(25) 3(1)* 13(20)*
Underlying disease
(GVHD/malignancy) 10(16) 2(6) 54(10) 43(8)
Other complications 17(27) 2(6) 63(12) 48(8)
*Death attributed to IFI by investigator, but not considered due to
IFI by blinded expert panel
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